Articles tagged with: ImMucin
Press Releases»
The FDA approval follows similar recognition for ImMucin from the EMA. This approval demonstrates the FDA's acknowledgement of an existing medical need for treatment of multiple myeloma and ImMucin's potential in treating this type of cancer.
Ness Ziona, Israel (Press Release) – Vaxil Bio, (TASE: VAXL) a company specializing in the development of immunotherapy-based drugs, reports today that its lead product, ImMucin, has been granted an "orphan drug" designation by the US Food and Drug Administration (FDA), for the treatment of multiple myeloma (MM).
ImMucin is an immunotherapeutic treatment which educates the MM …
Press Releases»
- Recognition of the unmet medical need and high therapeutic potential of ImMucin in Multiple Myeloma
- A multi-center phase II clinical study under IND is planned to start in Multiple Myeloma patients during 2015.
Ness Ziona, Israel (Press Release) – Vaxil Bio (TASE: VAXL), a leading developer of immunotherapeutic products to treat cancer and infectious diseases, reports today that its lead drug candidate, ImMucin has received orphan drug designation from the European Medicines Agency (EMA) of the European Commission (EC) for the treatment of Multiple Myeloma (MM), a …
News»
As The Beacon continues its ‘ASH Preview’ series about myeloma research that will be presented at the American Society of Hematology (ASH) meeting in early December, this article focuses on novel immunotherapy approaches that are being studied in clinical trials.
Abstracts for the ASH presentations are now available, although many contain preliminary information that will be updated at the meeting.
The Beacon’s ASH preview articles are intended to highlight the meeting’s most interesting myeloma-related studies.
The first several of the preview articles, which were published over the past …
NewsFlash »
Vaxil BioTherapeutics Initiates Phase 1/2 Clinical Trial Of ImMucin - Vaxil Biotherapeutics, a vaccine development company, has begun recruiting multiple myeloma patients for a Phase 1/2 clinical trial for its therapeutic vaccine ImMucin. Patients in the clinical trial will receive between six and twelve injections of ImMucin over three to six months. Researchers will follow up with patients for an additional six months. The clinical trial, which will evaluate the safety of ImMucin, will be held in Israel, where Vaxil is based. For more information, please see the Vaxil BioTherapeutics press release and the clinical trial description.
Senesco Plans Phase 1/2 Study Of SNS01-T – Senesco Technologies, a biotechnology company, announced plans to file by the end of 2010 for approval of a Phase 1a/2b study of SNS01-T in multiple myeloma patients. SNS01-T has shown promising results pre-clinical studies involving mice. If approved, the trial will begin in the first half of 2011. For more information, please see the Senesco press release.
International Society Of Hematology Congress – The International Society of Hematology will hold its 33rd annual congress in Jerusalem between October 10 and 13. Hematologists from around the world will gather to discuss the latest research, therapies, and tools available in the field. For more information, please see the Hematology Congress 2010 website.
Clinical Insights Educational Program – Dr. Robert Orlowski of the MD Anderson Cancer Center will be chairing an educational program in Houston on October 15. The program will feature seminars by some of the leading myeloma researchers, including Drs. Kenneth Anderson, Sagar Lonial, William Bensinger, Nikhil Munshi, and Irene Ghobrial. Seminar topics include front-line therapy, stem cell transplant, relapsed/refractory disease, supportive care, and clinical trials. The program will close with a question and answer panel by the faculty. For more information, please see the Multiple Myeloma Research Foundation website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.